283 related articles for article (PubMed ID: 21955006)
21. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
22. Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors.
Srivastava A; Muruganandham K; Vinodh PB; Singh P; Dubey D; Kapoor R; Kumar A; Sharma RK; Prasad N
Int Urol Nephrol; 2010 Jun; 42(2):279-84. PubMed ID: 19557542
[TBL] [Abstract][Full Text] [Related]
23. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
24. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
[TBL] [Abstract][Full Text] [Related]
25. Mammalian target of rapamycin (mTOR) inhibitors slow skin carcinogenesis, but impair wound healing.
Feldmeyer L; Hofbauer GF; Böni T; French LE; Hafner J
Br J Dermatol; 2012 Feb; 166(2):422-4. PubMed ID: 21895616
[TBL] [Abstract][Full Text] [Related]
26. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials.
Cooper M; Wiseman AC; Zibari G; McCague K; Kim Y; Geissler F; Nashan B
Clin Transplant; 2013; 27(6):E625-35. PubMed ID: 24033455
[TBL] [Abstract][Full Text] [Related]
27. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
28. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
29. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients.
Tiong HY; Flechner SM; Zhou L; Wee A; Mastroianni B; Savas K; Goldfarb D; Derweesh I; Modlin C
Transplantation; 2009 Jan; 87(2):296-302. PubMed ID: 19155988
[TBL] [Abstract][Full Text] [Related]
30. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.
Demopoulos L; Polinsky M; Steele G; Mines D; Blum M; Caulfield M; Adamkovic A; Liu Q; Harler MB; Hahn C; Singh A
Transplant Proc; 2008 Jun; 40(5):1407-10. PubMed ID: 18589118
[TBL] [Abstract][Full Text] [Related]
31. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.
Wolf S; Hoffmann VS; Habicht A; Kauke T; Bucher J; Schoenberg M; Werner J; Guba M; Andrassy J
PLoS One; 2018; 13(4):e0194975. PubMed ID: 29659588
[TBL] [Abstract][Full Text] [Related]
32. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
[TBL] [Abstract][Full Text] [Related]
33. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
34. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
35. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
36. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
37. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
38. mTOR inhibitors for management of encapsulating peritoneal sclerosis: a review of literatures.
Ghadimi M; Dashti-Khavidaki S; Khalili H
Ren Fail; 2016 Nov; 38(10):1574-1580. PubMed ID: 27425661
[TBL] [Abstract][Full Text] [Related]
39. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials.
Webster AC; Lee VW; Chapman JR; Craig JC
Transplantation; 2006 May; 81(9):1234-48. PubMed ID: 16699448
[TBL] [Abstract][Full Text] [Related]
40. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.
Kasiske BL; de Mattos A; Flechner SM; Gallon L; Meier-Kriesche HU; Weir MR; Wilkinson A
Am J Transplant; 2008 Jul; 8(7):1384-92. PubMed ID: 18510633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
